Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Campaign to Increase Compliance with Take-Home Colorectal Screening Test

By HospiMedica staff writers
Posted on 11 Apr 2008
A novel campaign has been launched help increase compliance with take-home colorectal screening tests. More...
The campaign aims to break down barriers to compliance with fecal occult blood tests and increase screening with convenient take-home screening tools. The goal of the new campaign is to have five million people complete their annual testing over the next five years.

In the United States, nearly 60 % of women have an annual Pap test (for cervical cancer) and as many as 79 % of men receive prostate-specific antigen (PSA) screening every year for prostate cancer. In one randomized clinical study, only 31 % of patients (n = 1818) completed an at-home colorectal screening test. Despite the availability of these convenient and effective diagnostic tests, nearly 150,000 men and women in the United States will be diagnosed with colorectal cancer this year, and one-third of these patients will ultimately succumb to the disease. When found early and treated, the five-year relative survival rate for colon cancer is 90%, but less than 40% of colorectal cancers are found early.

Fecal occult blood tests (FOBTs), including the newer fecal immunochemical tests (FITs), detect blood in the stool that might indicate colorectal cancer or other lower gastrointestinal diseases. These screening tests help identify individuals that are candidates for colonoscopy, even if they do not have overt symptoms of colorectal cancer. This may mean the disease is in its early, more treatable stages, or that they may have precancerous polyps that can be removed during colonoscopy.

Quest Diagnostics (Madison, NJ, USA) is launching the campaign at the end of Cancer Awareness Month "because we want people to remember that this disease strikes every day of every month,” said Stephen C. Suffin, M.D., the company's clinical pathologist and interim chief laboratory officer. "Our Challenge is designed to encourage people 50 and over and those at risk to complete annual screening with American Cancer Society [ACS] recommended tests, such as the FDA-[U.S. Food and Drug Administration]-approved, InSure FIT test and its painless, noninvasive Blue-Brush Method.”

The Challenge urges individuals to talk to their healthcare providers about annual colorectal cancer screening using the InSure FIT take-home test, developed by Quest, and in turn, to challenge friends and family members to "have the guts” to get screened, too. Challenge participants can also send an attention-grabbing "Happy, Healthy Colon” e-card to friends and relatives as a reminder to be screened annually. Medical professionals can access the latest scientific data on InSure FIT, up-to-date colorectal cancer screening guidelines and resources, and patient education materials that can help guide discussions with their patients about colorectal cancer screening.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.


Related Links:
Quest Diagnostics

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.